AEON Biopharma, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand AEON Biopharma’s performance this year. My goal is to translate complex filings into simple terms so you can decide if this company fits your investment strategy.

1. What does this company do?

AEON Biopharma is a "clinical-stage" biotech company. This means they are still in the lab and testing phase. Their entire business relies on one product: ABP-450, a botulinum toxin complex. They are targeting the $3.3 billion U.S. medical market for this toxin, specifically for conditions like cervical dystonia. Unlike cosmetic Botox, AEON focuses on medical treatments, which require strict FDA trials to prove they work.

2. How did they perform this year?

It has been a year of major changes. In mid-2024, the company stopped its migraine trial to focus resources on the cervical dystonia study, aiming to reach a final Phase 3 trial. They currently have no products on the market and have earned zero revenue from sales. Their only income has been minor interest, which is not enough to cover their research or administrative costs.

3. Financial health: The "Going Concern" Warning

The company is in a challenging financial position:

• The Losses: They reported a $12.8 million loss for 2025, down from $48.2 million in 2024. This decrease reflects the cost-cutting measures taken after they canceled the migraine trial.
• The Cash Crunch: As of December 31, 2025, they had only $3.0 million in cash remaining.
• The "Going Concern" Flag: The company has warned investors there is "substantial doubt" about their ability to stay in business. Their current cash cannot fund operations for the next 12 months. To survive, they must raise more capital, which will likely involve issuing new shares. This process would reduce your ownership percentage and the value of your current holdings.

4. Major risks: The "Regulatory" and "Competitive" Storm

Beyond the risk of running out of money, AEON faces several significant hurdles:

• Single Point of Failure: AEON does not own manufacturing facilities; they rely entirely on Daewoong Pharmaceutical to produce ABP-450. If Daewoong faces delays or supply issues, AEON has no backup, which would halt their progress.
• The Legal Shadow: AEON’s operations depend on a complex settlement involving Medytox, Daewoong, and Evolus. If these agreements are disrupted, AEON could lose the right to sell their product.
• Outsourced Risk: With only eight employees, AEON relies on outside firms to run clinical trials. If these firms make mistakes, the FDA could reject the entire trial, forcing a costly restart.
• Intellectual Property: AEON does not own the patents for ABP-450; they license them from Daewoong. They have limited control over these patents and face ongoing legal pressure from AbbVie, the maker of Botox.
• Big Pharma Competition: They compete against industry giants like AbbVie, which have the resources and legal power to outspend a smaller firm like AEON.

5. Future outlook

AEON is a high-stakes investment. They are currently burning through cash and depend entirely on outside partners for manufacturing and intellectual property. Their future hinges on successfully completing a Phase 3 trial and securing a partner to fund commercial sales. If they cannot raise additional capital soon, or if the FDA rejects their data, the company may be forced to cease operations or file for bankruptcy.

Investor Takeaway: When considering this stock, ask yourself if you are comfortable with a "binary" outcome. Because the company has no revenue and very little cash, your investment is essentially a bet on the success of their Phase 3 clinical trial and their ability to secure new funding. If those two things don't happen, the risk of losing your entire investment is high.